Cycle Pharmaceuticals Extends Tender Offer for Applied Therapeutics
Event summary
- Cycle Pharmaceuticals extended its tender offer for Applied Therapeutics until January 29, 2026.
- Approximately 44.32% of Applied Therapeutics' outstanding shares have been validly tendered as of January 28, 2026.
- The offer includes $0.088 per share plus one non-tradeable contingent value right per share.
- The tender is conditioned upon the acquisition of a majority of Applied Therapeutics' outstanding shares.
The big picture
Cycle Pharmaceuticals' extended tender offer for Applied Therapeutics reflects its strategic push into rare disease treatments. The acquisition aligns with Cycle's focus on metabolic, immunology, urology, oncology, and neurology conditions. The deal size and the contingent value rights indicate a long-term bet on Applied Therapeutics' pipeline success.
What we're watching
- Shareholder Response
- Whether the remaining shareholders will tender their shares before the new deadline.
- Regulatory Approval
- The pace at which regulatory approvals for the acquisition will be finalized.
- Integration Strategy
- How Cycle Pharmaceuticals plans to integrate Applied Therapeutics' operations and product portfolio.
Our editorial coverage:
Related topics